Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own

Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.

Abstract editorial illustration

Bear markets are inevitable in the stock market, but there are certain stocks that can provide stability and income during these periods. Johnson & Johnson, Medtronic, Coca-Cola, and Procter & Gamble are among the companies that have shown resilience in economically robust industries and have a long history of paying dividends. Johnson & Johnson, a major player in pharmaceuticals and medical devices, offers a Dividend King status with over 50 consecutive annual increases to shareholders.

Medtronic, while not yet a Dividend King, provides a larger 3% yield and has recently introduced innovative products like its Hugo surgical robot, which is expected to spur growth. Consumer staples such as Coca-Cola and Procter & Gamble are also attractive options, as they sell essential products that people will continue to purchase even in a bear market.

Both companies have Dividend King status and have shown impressive growth, with Coca-Cola managing a 6% increase in organic sales in the second quarter of 2026. Procter & Gamble's focus on innovation and offering products with real benefits to consumers further strengthens its appeal as a safe-haven investment ahead of a potential bear market.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 2 other outlets

Read the original at fool.com →

More in Finance & Markets

Is AbbVie a Buy After Its Latest Earnings Report?

Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.

  • AbbVie's Q3 revenue up 10.3% to $17.4 billion
  • Skyrizi and Rinvoq drive 48.7% of total revenue
  • AbbVie raises full-year adjusted EPS guidance and dividend

More from Saturday 31 October →